Global law firm White & Case LLP has advised IK Investment Partners and Merieux Equity Partners on the acquisition of Mabtech.
Mabtech, founded in Sweden in 1986 has gained worldwide recognition for its high quality monoclonal antibodies and technical innovation capabilities and is viewed as a pioneer within the growing detection platform techniques of ELISpot and FluoroSpot. To complement its offering, Mabtech successfully entered the instruments market by launching its first reader, IRIS, in December 2018. Mabtech's products are used by researchers and companies worldwide to study immune responses, including in cases of cancer, allergy and infectious diseases, and to monitor vaccine trials.
IK Investment Partners is a Pan-European private equity firm focused on investments in the Nordics, DACH region, France, and Benelux. Since 1989, IK has raised more than €10 billion of capital and invested in over 125 European companies. IK funds support companies with strong underlying potential, partnering with management teams and investors to create robust, well-positioned businesses with excellent long-term prospects.
Mérieux Equity Partners is dedicated to venture capital and growth equity investments operating as a multi-stage investment manager, dedicated to evidence-based investment in companies that are developing superior products and services within the healthcare, life science and nutrition market segments. Mérieux has committed over €350 million in financing across 30 companies, in both venture and growth capital.
The White & Case team which advised on the transaction was led by partners Shoan Panahi (Stockholm), Nathalie Nègre-Eveillard (Paris) and Carl Hugo Parment (Stockholm) with support from counsels Sara Nordin (Geneva, Brussels) and Estelle Philippi (Paris), associates Sebastian Wallin, David Riihonen, Jonas Johansson, Emelie Bimer, Ivana Sutalo, Petar Bojovic, Kajsa Sundklev and Johanna Wagner (all Stockholm) and Sophie Nguyen (Paris).
For more information, please speak to your local media contact.